The collaboration aims to leverage the combined strengths of development, manufacturing and commercialization of biosimilars. The move is expected to benefit patients across the globe.
Holzkirchen/Germany – Sandoz, a Novartis division and the global leader in biosimilars, has recently announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon. With this, both the companies will develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.
Under the terms of the agreement, the companies will also share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products, and will have a cost and profit share arrangement globally. Worldwide commercialization responsibilities will be divided and each company’s strengths will be leveraged within specific geographies. Sandoz will lead commercialization in North America and the EU, while Biocon will lead commercialization in Rest of the World.